Zobrazeno 1 - 10 of 36 pro vyhledávání: '"K D, Lindor"'
1
Cholestatic Liver Disease
Autor: K. D. Lindor, J. A. Talwalkar
Publikováno v: Clinical Gastroenterology ISBN: 9781493910120
Cholestatic Liver Disease
Chapter 1 Diagnosis of Cholestasis Andrea A. Gossard Chapter 2 Drug-Induced Cholestasis Einar S. Bjornsson Chapter 3 Primary Biliary Cirrhosis Marina G. Silveira Chapter 4 Primary Sclerosing Cholangitis Meredith Borman and Bertus Eksteen Chapter 5 Ig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4f3955c12017b2e1f7da3cfffea70d40
https://doi.org/10.1007/978-1-4939-1013-7
Zobrazit plný text záznamu
2
Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis
Autor: P, Angulo, O, El-Amin, H A, Carpenter, K D, Lindor
Publikováno v: The American Journal of Gastroenterology. 96:3021-3027
Primary biliary cirrhosis and autoimmune hepatitis, the most common autoimmune liver diseases in adults, are frequently easily differentiated by a combination of clinical, biochemical, and histological features along with the presence of highly sensi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::531771c81fc541c32307f50a3344cbec
https://doi.org/10.1111/j.1572-0241.2001.04675.x
Zobrazit plný text záznamu
3
Balloon Dilation Compared To Stenting of Dominant Strictures in Primary Sclerosing Cholangitis
Autor: M, Kaya, B T, Petersen, P, Angulo, T H, Baron, J C, Andrews, C J, Gostout, K D, Lindor
Publikováno v: American Journal of Gastroenterology. 96:1059-1066
In some patients with primary sclerosing cholangitis (PSC), a localized, high-grade (dominant) stricture may be the principal cause of symptoms and hyperbilirubinemia. The aim of this retrospective study was to compare the beneficial effects and risk
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6740a855c1cfa2b17837f058f826ab
https://doi.org/10.1111/j.1572-0241.2001.03690.x
Zobrazit plný text záznamu
4
Time Course of Histological Progression in Primary Sclerosing Cholangitis
Autor: P, Angulo, D R, Larson, T M, Therneau, N F, LaRusso, K P, Batts, K D, Lindor
Publikováno v: American Journal of Gastroenterology. 94:3310-3313
The aim of this study was to determine the time course over which patients with primary sclerosing cholangitis (PSC) progress through the histological stages of the disease.One hundred seven patients with PSC who had at least two liver biopsies were
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ab66a94fce4e55db800966098dccaf9
https://doi.org/10.1111/j.1572-0241.1999.01543.x
Zobrazit plný text záznamu
5
An update on primary sclerosing cholangitis:from pathogenesis to treatment
Autor: M H, Imam, J A, Talwalkar, K D, Lindor
Publikováno v: Minerva gastroenterologica e dietologica. 59(1)
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology despite advances in medical research that have focused on uncovering its pathogenesis. Recent developments in the diagnosis of PSC including technological
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c8314371d64141ed366f9fcf523495ad
https://pubmed.ncbi.nlm.nih.gov/23478243
Zobrazit plný text záznamu
7
Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis
Autor: M H, Imam, E W, Thackeray, K D, Lindor
Publikováno v: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 15(2)
Current guidelines recommend annual surveillance for colorectal cancer (CRC) in all patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The aim of our study was to validate the need for annual surveillance for col
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8a48e5b4d841be012f7798f3fe9ed56e
https://pubmed.ncbi.nlm.nih.gov/22712545
Zobrazit plný text záznamu
8
The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study
Autor: C R, Martin, P G, Blanco, J C, Keach, J L, Petz, M M, Zaman, K R, Bhaskar, J E, Cluette-Brown, S, Gautam, S, Sheth, N H, Afdhal, K D, Lindor, S D, Freedman
Publikováno v: Alimentary pharmacologytherapeutics. 35(2)
Primary sclerosing cholangitis (PSC) is characterised by progressive inflammatory and fibrotic destruction of the biliary ducts. There are no effective medical therapies and presently high dose ursodeoxycholic acid is no longer recommended due to sig
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2034850e7ee8f7c7f591d978d47fbf49
https://pubmed.ncbi.nlm.nih.gov/22129201
Zobrazit plný text záznamu
9
High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis
Autor: M H, Imam, E, Sinakos, A A, Gossard, K V, Kowdley, V A C, Luketic, M, Edwyn Harrison, T, McCashland, A S, Befeler, D, Harnois, R, Jorgensen, J, Petz, J, Keach, A C, DeCook, F, Enders, K D, Lindor
Publikováno v: Alimentary pharmacologytherapeutics. 34(10)
Ursodeoxycholic acid (UDCA) in a dose of 28-30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients.To compare the risk of adverse clinical endpoints in patients with varying disease status.We
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d69c7a0db7bedacd5699032c2a1632ae
https://pubmed.ncbi.nlm.nih.gov/22300127
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje